A number of linear and conformation-dependent neutralizing monoclonal antibodies (MAbs) have been mapped to the first and second variable (Vi and V2) domains of human immunodeficiency virus type 1 (HIV-1) gp120. The majority of these MAbs are as effective at neutralizing HIV-i infectivity as MAbs to the V3 domain and the CD4 binding site. The linear MAbs bind to amino acid residues 162 to 171, and changes at residues 183/184 (PI/SG) and 191/192/193 (YSVGSS) within the V2 domain abrogate the binding of the two conformation-dependent MAbs, 11/68b and CRA-4, respectively. Surprisingly, a change at residue 435 (Y/
AbstractDifferent isolates of HIV-1 are known to vary in antibody binding and sensitivity to neutral...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
In the case-control study of the RV144 vaccine trial, the levels of antibodies to the V1V2 region of...
Preservation of the conformation of recombinant gpl20 in an adjuvant, enabling it to elicit conforma...
Recent studies have shown that natural infection by HIV-2 leads to the elicitation of high titers of...
We have raised antisera and monoclonal antibodies (MAbs) to the C4 region of HIV-1 gp120, using an a...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
We have probed the structure of the C4 and V3 domains of human immunodeficiency virus type 1 gp120 b...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
We investigated the relative importance of binding site occupancy and epitope specificity in antibod...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
AbstractTwenty-five conformation-dependent monoclonal antibodies (MAbs) produced by immunization of ...
AbstractDifferent isolates of HIV-1 are known to vary in antibody binding and sensitivity to neutral...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...
We have analyzed a panel of eight murine monoclonal antibodies (MAbs) that depend on the V2 domain f...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
In the case-control study of the RV144 vaccine trial, the levels of antibodies to the V1V2 region of...
Preservation of the conformation of recombinant gpl20 in an adjuvant, enabling it to elicit conforma...
Recent studies have shown that natural infection by HIV-2 leads to the elicitation of high titers of...
We have raised antisera and monoclonal antibodies (MAbs) to the C4 region of HIV-1 gp120, using an a...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
We have probed the structure of the C4 and V3 domains of human immunodeficiency virus type 1 gp120 b...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
We investigated the relative importance of binding site occupancy and epitope specificity in antibod...
The envelope glycoproteins of HIV, gp120 and gp41, contain epitopes recognized by neutralizing antib...
AbstractTwenty-five conformation-dependent monoclonal antibodies (MAbs) produced by immunization of ...
AbstractDifferent isolates of HIV-1 are known to vary in antibody binding and sensitivity to neutral...
A subset of the neutralizing anti-HIV antibodies recognize epitopes on the envelope protein gp120 of...
Abstract Background The CD4-induced (CD4i) epitopes in gp120 includes the co-receptor binding site, ...